CRISPR-Cas9 is a promising tool against genetic disease, but it comes with
some safety concerns, namely, off-target gene editing that may bring about
harmful side effects such as cancer. UC Berkeley scientists are using a new
delivery system to more safely correct the mutated dystrophin gene in mouse
models of Duchenne muscular dystrophy.
Sorry, the comment form is closed at this time.